Analysis of miRNA Expression in Patients with Rheumatoid Arthritis during Olokizumab Treatment
Authors:
- Irina V. BureIBIrina V. Bure
- Dmitry S. MikhaylenkoDMDmitry S. Mikhaylenko
- Ekaterina B. KuznetsovaEKEkaterina B. Kuznetsova
- Ekaterina A. AlekseevaEAEkaterina A. Alekseeva
- Kristina I. BondarevaKBKristina I. Bondareva
- Alexey I. KalinkinAKAlexey I. Kalinkin
- Alexander N. LukashevALAlexander N. Lukashev
- Vadim V. TarasovVTVadim V. Tarasov
- Andrey A. ZamyatninAndrey A. Zamyatnin
- Marina V. NemtsovaMNMarina V. Nemtsova
Open Access
- 31 October 2020
- journal article
- research article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 10 (4) , 205
Abstract
Rheumatoid arthritis (RA) is the most common autoimmune disease worldwide. Epigenetic alternations of microRNAs (miRNAs) can contribute to its pathogenesis and progression. As the first line therapy with DMARDs is not always successful, other drugs and therapeutic targets should be applied. This study aims to measure the expression level of plasma miRNAs in RA patients treated with olokizumab and to evaluate their potential as prognostic biomarkers. The expression of 9 miRNAs was quantified in 103 RA patients before treatment and at weeks 12 and 24 of olokizumab therapy by reverse transcription-polymerase chain reaction (RT-PCR) assay and analyzed in groups of responders and non-responders. Almost all miRNAs changed their expression during therapy. The ROC curve analysis of the most prominent of them together with consequent univariate and multivariate regression analysis revealed statistically significant associations with the olokizumab therapy efficiency scores for miR-26b, miR-29, miR-451, and miR-522. Therefore, these miRNAs might be a potential therapeutic response biomarker.Keywords
Funding Information
- Ministry of Education and Science of the Russian Federation (unique project ID RFMEFI60518X0003)
This publication has 45 references indexed in Scilit:
- RETRACTED: Rheumatoid Arthritis-Associated MicroRNA-155 Targets SOCS1 and Upregulates TNF-α and IL-1β in PBMCsInternational Journal of Molecular Sciences, 2013
- MiR-20a regulates ASK1 expression and TLR4-dependent cytokine release in rheumatoid fibroblast-like synoviocytesAnnals of the Rheumatic Diseases, 2013
- Upregulated MicroRNA-155 Expression in Peripheral Blood Mononuclear Cells and Fibroblast-Like Synoviocytes in Rheumatoid ArthritisJournal of Immunology Research, 2013
- MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritisProceedings of the National Academy of Sciences, 2011
- A study of miRNAs targets prediction and experimental validationProtein & Cell, 2010
- The role of Interleukin 6 in the pathophysiology of rheumatoid arthritisTherapeutic Advances in Musculoskeletal Disease, 2010
- NAViGaTOR: Network Analysis, Visualization and Graphing TorontoBioinformatics, 2009
- Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritisArthritis & Rheumatism, 2008
- Treatment of rheumatoid arthritisAmerican Journal of Health-System Pharmacy, 2006
- miR-15 and miR-16 induce apoptosis by targeting BCL2Proceedings of the National Academy of Sciences, 2005